2024
Meta-analysis: The utility of the anterior quadratus lumborum block in abdominal surgery
Evans B, Ihnat J, Zhao K, Kim L, Pierson D, Yu C, Lin H, Li J, Golshan M, Ayyala H. Meta-analysis: The utility of the anterior quadratus lumborum block in abdominal surgery. The American Journal Of Surgery 2024, 239: 116014. PMID: 39454308, DOI: 10.1016/j.amjsurg.2024.116014.Peer-Reviewed Original ResearchAnterior quadratus lumborum blockTransversus abdominis planeTransversus abdominis plane blockQuadratus lumborum blockAbdominal surgeryRandomized controlled trialsMorphine equivalentsPost-operativelyMeta-analysisTotal oral morphine equivalentsPost-operative opioid consumptionPost-operative pain scoresOral morphine equivalentsPost-operative recovery timeRandom-effects meta-analysisOpioid consumptionPain scoresOpioid useSurgery typeNon-inferioritySurgeryPresence of confounding variablesRegional anesthesiaQuadratus lumborumSurgery pathwayASO Visual Abstract: National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. ASO Visual Abstract: National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 1-1. DOI: 10.1245/s10434-024-16259-9.Peer-Reviewed Original ResearchNational Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer
Kim L, Moore M, Schneider E, Canner J, Ayyala H, Chen J, Anant P, Graetz E, Lynch M, Zanieski G, Gillego A, Valero M, Proussaloglou E, Berger E, Golshan M, Greenup R, Park T. National Patterns of Hospital Admission Versus Home Recovery Following Mastectomy for Breast Cancer. Annals Of Surgical Oncology 2024, 1-12. PMID: 39322830, DOI: 10.1245/s10434-024-16107-w.Peer-Reviewed Original ResearchHR patientsLymph nodesRate of neoadjuvant chemotherapyHospital admissionNational patterns of careEmergency departmentDecrease wound complicationsNeoadjuvant chemo-Hospital re-admissionNeoadjuvant chemotherapyIn-hospital admissionRate of reconstructionPerioperative outcomesPostoperative hematomaComplication ratePostoperative complicationsWound complicationsHome recoveryPatterns of careBreast cancerMastectomyEmergency room visitsMultivariate analysisComplicationsPatientsIncidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers
Dey P, Kc M, Proussaloglou E, Khubchandani J, Kim L, Zanieski G, Park T, Lynch M, Gillego A, Valero M, Schneider E, Golshan M, Greenup R, Berger E. Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. Annals Of Surgical Oncology 2024, 1-8. PMID: 39240394, DOI: 10.1245/s10434-024-16124-9.Peer-Reviewed Original ResearchTriple-negative breast cancerClinically node-negativePathologically node-negativePN+ diseaseNode-negativeBreast cancerYears of ageNodal diseaseHR-/HER2Significant comorbiditiesEpidermal growth factor receptor 2-positiveOdds of node positivityRate of nodal diseaseTriple-positive breast cancerTriple positive breast cancerEarly-stage breast cancerHR-positive/HER2-negativePathologic nodal diseasePathologic nodal positivityPredictors of pN+T1a breast cancerHR-/HER2+Sentinel node biopsyNational Cancer DatabasePathologic nodal stageASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Switalla K, Boughey J, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait L, Piltin M, Reyna C, Matsen C, Tuttle T, Wallace A, Arciero C, Lee M, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman L, Mukhtar R. ASO Visual Abstract: Clipping the Positive Lymph Node in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7262-7263. DOI: 10.1245/s10434-024-15965-8.Peer-Reviewed Original ResearchASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy—Results from the I-SPY2 Clinical Trial
Piltin M, Norwood P, Ladores V, Mukhtar R, Sauder C, Golshan M, Tchou J, Rao R, Lee M, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman L, Boughey J. ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy—Results from the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7429-7430. DOI: 10.1245/s10434-024-15917-2.Peer-Reviewed Original ResearchClipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Switalla K, Boughey J, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait L, Piltin M, Reyna C, Matsen C, Tuttle T, Wallace A, Arciero C, Lee M, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman L, Mukhtar R. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7249-7259. PMID: 38995451, PMCID: PMC11452431, DOI: 10.1245/s10434-024-15792-x.Peer-Reviewed Original ResearchPositive lymph nodesEvent-free survivalNeoadjuvant chemotherapyAxillary surgeryClip placementLymph nodesPN+ diseasePositive nodesNode-positive breast cancer treated with neoadjuvant chemotherapyBreast cancer treated with neoadjuvant chemotherapyOmission of axillary dissectionSentinel lymph node biopsyClinically node-positiveNeoadjuvant chemotherapy trialsPathologically node-positiveLymph node biopsySurgical management strategiesProportion of patientsMultivariate logistic regressionNode-positiveAssociated with higher oddsCN+ patientsPre-NACNode biopsyAxillary dissectionTailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, Saghir N, Penault‐Llorca F, Perez E, Poortmans P, Abdelaziz H, El‐Zawahry H, Kassem L, Sabry M, Viale G, Al‐Sukhun S, Gado N, Leung J, Elarab L, Cardoso M, Karim K, Foheidi M, Elmaadawy M, Conte P, Selim A, Kandil A, Kamal R, Paltuev R, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel‐Aziz A, Eldin N. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations. Cancer 2024, 130: 3251-3271. PMID: 38985794, DOI: 10.1002/cncr.35389.Peer-Reviewed Original ResearchBreast cancerNeoadjuvant therapyManagement of early breast cancerEarly breast cancerIndividual patient managementDe-escalation strategiesModified Delphi approachBC expertsPostneoadjuvant treatmentSystemic therapyClinical evidencePatient managementConsensus recommendationsClinical situationsTherapyDe-escalationDelphi approachTherapy outcomeTreatment settingsCancerExpert opinionRecommendationsBreastConsensusInternal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial
Piltin M, Norwood P, Ladores V, Mukhtar R, Sauder C, Golshan M, Tchou J, Rao R, Lee M, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman L, Boughey J. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Annals Of Surgical Oncology 2024, 31: 7420-7428. PMID: 38980586, DOI: 10.1245/s10434-024-15708-9.Peer-Reviewed Original ResearchPathological complete responseEvent-free survivalPatients treated with neoadjuvant chemotherapyNeoadjuvant chemotherapyDistant recurrenceLocoregional recurrenceOncological outcomesClinical trialsRate of locoregional recurrenceResponse to neoadjuvant chemotherapyInternal mammary lymphadenopathyModern neoadjuvant chemotherapyHigh tumor gradeMethodsWe evaluated patientsBreast cancer stageAxillary surgeryComplete responseMedian followTumor gradePretreatment imagingLarger tumorsPrognostic indicatorI-SPY2Comparing patientsCancer stageComparison of magnetic seed and RFID methods in the localization of non-palpable breast lesions.
Sanli A, Tekcan Sanli D, Golshan M, Sezgin E, Celik V, Aydogan F. Comparison of magnetic seed and RFID methods in the localization of non-palpable breast lesions. Journal Of Cancer Research And Therapeutics 2024, 20: 1435-1439. PMID: 39412908, DOI: 10.4103/jcrt.jcrt_2253_22.Peer-Reviewed Original ResearchNon-palpable breast lesionsSurgical margin negativityTotal resection volumeMargin negativityResection volumeBreast lesionsLocalization of non-palpable breast lesionsSurgical margin distanceRe-excision ratesWire-guided localizationExcised tissue weightBreast lesion localizationRe-excisionSurgical resultsIncision lengthProcedure timeMagseedTurkey breastOperative timeMargin distanceLesion localizationBreastLesionsSuccess rateTissue weight
2023
Great Debate: The Surgeon’s Role in Locoregional Management of Stage IV Breast Cancer
Lucci A, Kim L, Golshan M, King T. Great Debate: The Surgeon’s Role in Locoregional Management of Stage IV Breast Cancer. Annals Of Surgical Oncology 2023, 30: 7000-7007. PMID: 37596450, DOI: 10.1245/s10434-023-14134-7.Peer-Reviewed Original Research
2022
Regional block pilot for microvascular free-flap breast reconstruction.
Kim L, Long A, Miller J, Zurich H, Golshan M, Li J. Regional block pilot for microvascular free-flap breast reconstruction. Journal Of Clinical Oncology 2022, 40: e18646-e18646. DOI: 10.1200/jco.2022.40.16_suppl.e18646.Peer-Reviewed Original ResearchAnterior quadratus lumborum blockDeep inferior epigastric perforatorDIEP flap reconstructionERAS pathwayERAS protocolBaseline patientBreast reconstructionFlap reconstructionMicrovascular free flap breast reconstructionPost-anesthesia care unit lengthQuaternary care academic centerFree flap breast reconstructionTransversus abdominus plane blockDaily opioid consumptionPain control modalitiesAverage pain scoreQuadratus lumborum blockMicrosurgical breast reconstructionContinuous quality improvement projectDirect ultrasound guidanceInferior epigastric perforatorQuality improvement projectPilot groupEvidence-based approachOpioid consumptionLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Geyer C, Sikov W, Huober J, Rugo H, Wolmark N, O’Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Rastogi P, Sohn J, Young R, Wright G, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals Of Oncology 2022, 33: 384-394. PMID: 35093516, DOI: 10.1016/j.annonc.2022.01.009.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEvent-free survivalAddition of carboplatinNeoadjuvant chemotherapyOverall survivalHazard ratioBreast cancerEarly-stage triple-negative breast cancerPathological complete response rateRandomized phase III trialComplete response rateCyclophosphamide neoadjuvant chemotherapyManageable acute toxicitiesManageable safety profileSafety of additionUntreated stage IIStandard neoadjuvant chemotherapyPhase III trialsCo-primary endpointsLong-term efficacyAcute myeloid leukemiaWeekly paclitaxelPrimary endpointSecondary endpointsIII trialsASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates
Le Blanc J, Golshan M, Lannin D, Greenup R, Berger E, Saridakis A, Horowitz N, Zanieski G, Avraham T, Mastrioanni M, Park T. ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates. Annals Of Surgical Oncology 2022, 29: 2191-2192. DOI: 10.1245/s10434-021-10944-9.Peer-Reviewed Original Research
2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant chemotherapyCohort studyBreast cancerInstability scoreGenomic instability scoreGermline BRCA mutation carriersPathologic complete response rateAddition of carboplatinComplete response rateStandard neoadjuvant chemotherapyLymph node statusBRCA mutation carriersGermline BRCA1/2 mutationsNegative breast cancerOverall cohortNode statusTreatment armsHigher oddsMutation carriersBRCA1/2 mutationsResponse rateCarboplatinPARP inhibitorsCancerASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers
Saridakis A, Berger ER, Greenup R, Golshan M, Lannin DR. ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers. Annals Of Surgical Oncology 2021, 29: 581-582. PMID: 34743280, DOI: 10.1245/s10434-021-10649-z.Peer-Reviewed Original ResearchThe Impact of COVID-19 on Breast Surgery Fellowships
Friedrich AU, DiComo JA, Golshan M. The Impact of COVID-19 on Breast Surgery Fellowships. Current Breast Cancer Reports 2021, 13: 235-240. PMID: 34703524, PMCID: PMC8531885, DOI: 10.1007/s12609-021-00430-2.Peer-Reviewed Original ResearchSurgical oncology fellowsOncology fellowsSurgery fellowshipFellowship trainingSurgical oncology fellowshipsFuture patient careElective casesLong-term consequencesPatient careOncology fellowshipsMultidisciplinary approachCOVID-19COVID-19 pandemicWay physiciansPandemic spreadDeadly pandemicCOVID-19 virusAdditional researchPandemicMedical trainingFellowshipPhysiciansSurgeonsFellowsExploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery
Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.Peer-Reviewed Original ResearchConceptsCancer treatment-related symptomsPrehabilitation interventionsTreatment-related symptomsTime of enrollmentImpact of exerciseQuality of lifeBreast cancerGroup participantsPre-operative exerciseBreast cancer surgeryMind-body interventionsCognitive functioningOpportunity trialCancer surgeryOutcome measuresSecondary analysisOne monthSurgeryMeasures of qualityGroup comparisonsCancer diagnosisCancerWomenInterventionSignificant differencesASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program
Pak L, Purad C, Nadipally S, Rao M, Mukherjee S, Hegde S, Golshan M. ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 727-728. DOI: 10.1245/s10434-021-10470-8.Peer-Reviewed Original ResearchInterim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery
Basu SS, Stopka SA, Abdelmoula WM, Randall EC, Gimenez-Cassina Lopez B, Regan MS, Calligaris D, Lu FF, Norton I, Mallory MA, Santagata S, Dillon DA, Golshan M, Agar NYR. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. Npj Breast Cancer 2021, 7: 116. PMID: 34504095, PMCID: PMC8429658, DOI: 10.1038/s41523-021-00318-5.Peer-Reviewed Original ResearchIntraoperative mass spectrometrySurgical marginsBreast cancerTime of surgeryInvasive breast cancerBreast cancer surgeryRegistered clinical trialsBreast cancer tissuesBreast cancer marginsClinical trial analysisPost-surgery analysisSuch resectionsCancer surgerySurgical specimensClinical trialsHistopathological determinationOptimal resectionUninvolved regionsCancer tissuesTumor breastBreast tumorsCandidate biomarkersLipidomic profilesPathological techniquesNormal tissues